Novus Biologicals products are now on bio-techne.com

CD8

Is Monkeypox Still A Threat?

Tired T cells: Hypoxia Drives T cell Exhaustion in the Tumor Microenvironment

Synthetic Biotic Medicine as Immunotherapy Against Cancer: Evidence From Arginine-Producing Engineered Bacteria

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy

Early T cell response is associated with mild COVID-19 and rapid SARS-CoV-2 clearance

Approved COVID-19 Vaccines: Delivery of Nucleic Acid Cargo and Immune Response

Success of combined IL-10 and IL-12 therapy in colon cancer depends on IFN-gamma and gut barrier integrity

mTOR Signaling and the Tumor Microenvironment

CAR-T Cell Therapy: Refining the Approach in Solid Tumors

CAR-T Cell Killing

By Jacqueline Carrico, BS, MD Candidate

The role of MHC Class II RT1B and immune response post brain injury

The major histocompatibility complex (MHC) is responsible for binding peptide fragments arising from pathogens in order to display them on the cell surface for recognition from immune cells.  Once recognized, the foreign pathogen is typically evaded. The MHC complex is broken into two categories, MHC Class I proteins and MHC Class II proteins.  MHC complex I and II proteins are all very different and contain specific molecules to bind different peptides – in fact, they have been described as the most polymorphic genes there are.

Pages